Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Operating Income (2016 - 2023)

Endonovo Therapeutics has reported Operating Income over the past 12 years, most recently at -$472797.0 for Q3 2023.

  • Quarterly results put Operating Income at -$472797.0 for Q3 2023, up 4.83% from a year ago — trailing twelve months through Sep 2023 was $33.6 million (up 1166.47% YoY), and the annual figure for FY2022 was $33.0 million, up 1582.12%.
  • Operating Income for Q3 2023 was -$472797.0 at Endonovo Therapeutics, up from -$1.1 million in the prior quarter.
  • Over the last five years, Operating Income for ENDV hit a ceiling of $35.8 million in Q4 2022 and a floor of -$1.8 million in Q2 2022.
  • Median Operating Income over the past 5 years was -$601826.0 (2020), compared with a mean of $2.7 million.
  • Peak annual rise in Operating Income hit 9672.46% in 2022, while the deepest fall reached 215.54% in 2022.
  • Endonovo Therapeutics' Operating Income stood at -$729997.0 in 2019, then surged by 4090.19% to $29.1 million in 2020, then tumbled by 101.28% to -$373794.0 in 2021, then soared by 9672.46% to $35.8 million in 2022, then tumbled by 101.32% to -$472797.0 in 2023.
  • The last three reported values for Operating Income were -$472797.0 (Q3 2023), -$1.1 million (Q2 2023), and -$529290.0 (Q1 2023) per Business Quant data.